DARIEN, Conn., Nov. 27, 2024 /PRNewswire/ — For the first time, researchers have examined the safety and efficacy of migraine neuromodulation therapy across subtypes of migraine-associated most bothersome symptoms (MBS). These researchers conducted a post hoc analysis of the TEAM (Trial…